Oral Oncology
Volume 46, Issue 8 , Pages 607-611 , August 2010

Role of adjuvant chemotherapy in malignant mucosal melanoma of the head and neck

  • Heui June Ahn

      Affiliations

    • Division of Hematology–Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • Division of Oncology, Department of Internal Medicine, Asan Medical Center, Seoul, Republic of Korea
    • These authors contributed equally.
    • ,
  • Im II Na

      Affiliations

    • Division of Hematology–Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • These authors contributed equally.
    • ,
  • Yeon Hee Park

      Affiliations

    • Division of Hematology–Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • Division of Hematology–Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Division of Hematology–Oncology, Department of medicine, Samsung Medical Center, 50, Irwon-Dong, Gangnam-Gu, Seoul 135-710, Republic of Korea. Tel.: +82 2 3410 1780; fax: +82 2 3410 1757.
    • ,
  • Soo Youn Cho

      Affiliations

    • Department of Pathology, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • ,
  • Byeong Cheol Lee

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • ,
  • Guk Haeng Lee

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • ,
  • Jae Soo Koh

      Affiliations

    • Department of Pathology, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • ,
  • Yong Sik Lee

      Affiliations

    • Department of Pathology, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • ,
  • Yoon Sang Shim

      Affiliations

    • Department of Pathology, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • ,
  • Yong Kack Kim

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • ,
  • Hye Jin Kang

      Affiliations

    • Division of Hematology–Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • ,
  • Baek-Yeol Ryoo

      Affiliations

    • Division of Hematology–Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Republic of Korea
    • Division of Oncology, Department of Internal Medicine, Asan Medical Center, Seoul, Republic of Korea
    • ,
  • Sung Hyun Yang

      Affiliations

    • Division of Hematology–Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Republic of Korea

Received 9 April 2010 ,Revised 17 May 2010 ,Accepted 25 May 2010.

References 

  1. Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American college of surgeons commission on cancer and the American cancer society. Cancer. 1998;83:1664–1678
  2. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg. 2003;129:864–868
  3. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 1997;80:1373–1386
  4. Prasad ML, Patel SG, Huvos AG, Shah JP, Busam KJ. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, stage I (lymph node-negative) tumors. Cancer. 2004;100:1657–1664
  5. Shah JP, Huvos AG, Strong EW. Mucosal melanomas of the head and neck. Am J Surg. 1977;134:531–535
  6. Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg. 1975;182:572–575
  7. Day CL, Lew RA, Mihm MC, Harris MN, Kopf AW, Sober AJ, et al. The natural break points for primary-tumor thickness in clinical stage I melanoma. N Engl J Med. 1981;305:1155
  8. Temam S, Mamelle G, Marandas P, Wibault P, Avril MF, Janot F, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103:313–319
  9. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005;6:438–439
  10. Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24:247–257
  11. Prasad ML, Busam KJ, Patel SG, Hoshaw-Woodard S, Shah JP, Huvos AG. Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med. 2003;127:997–1002
  12. Prasad ML, Patel S, Hoshaw-Woodard S, Escrig M, Shah JP, Huvos AG, et al. Prognostic factors for malignant melanoma of the squamous mucosa of the head and neck. Am J Surg Pathol. 2002;26:883–892
  13. Whiteman DC, Parsons PG, Green AC. P53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer. 1998;77:843–848
  14. Kaplan EL, Meier MP. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  15. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;44:793–797
  16. Brookmeyer R, Crowley J. A confidence interval for median survival time. Biometrics. 1982;38:29–41
  17. Rapidis AD, Apostolidis C, Vilos G, Valsamis S. Primary malignant melanoma of the oral mucosa. J Oral Maxillofac Surg. 2003;61:1132–1139
  18. Yii NW, Eisen T, Nicolson M, A’Hern R, Rhys-Evans P, Archer D, et al. Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. Clin Oncol (R Coll Radiol). 2003;15:199–204
  19. Lee SP, Shimizu KT, Tran LM, Juillard G, Calcaterra TC. Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope. 1994;104:121–126
  20. Nakaya M, Mochiki M, Takeuchi S, Yuge T, Nakao K, Nakamura N, et al. Malignant melanoma of nasal cavity: report of 16 Japanese patients. Auris Nasus Larynx. 2004;31:233–237
  21. Regezi JA, Hayward JR, Pickens TN. Superficial melanomas of oral mucous membranes. Oral Surg Oral Med Oral Pathol. 1978;45:730–740
  22. Snow GB, van der Waal I. Mucosal melanomas of the head and neck. Otolaryngol Clin North Am. 1986;19:537–547
  23. Wada H, Nemoto K, Ogawa Y, Hareyama M, Yoshida H, Takamura A, et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys. 2004;59:495–500
  24. Hussein MR, Haemel AK, Wood GS. P53-related pathways and the molecular pathogenesis of melanoma. Eur J Cancer Prev. 2003;12:93–100
  25. Pandey M, Mathew A, Iype EM, Sebastian P, Abraham EK, Nair KM. Primary malignant mucosal melanoma of the head and neck region: pooled analysis of 60 published cases from India and review of literature. Eur J Cancer Prev. 2002;11:3–10
  26. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res. 2001;61:7642–7646
  27. Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 2002;94:1803–1806
  28. Gwosdz C, Scheckenbach K, Lieven O, Reifenberger J, Knopf A, Bier H, et al. Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer. 2005;118:577–582
  29. Ilmonen S, Hernberg M, Pyrhonen S, Tarkkanen J, Asko-Seljavaara S. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res. 2005;15:375–381
  30. Kakehi Y, Ozdemir E, Habuchi T, Yamabe H, Hashimura T, Katsura Y, et al. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res. 1998;89:214–220
  31. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol. 1997;9:79–87
  32. Brantley MA, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000;157:1795–1801

☆ We state that this report is original and that there have been no previous presentations, reports, or publications related to this study.

PII: S1368-8375(10)00167-3

doi: 10.1016/j.oraloncology.2010.05.005

Oral Oncology
Volume 46, Issue 8 , Pages 607-611 , August 2010

Article Tools

* Image Usage & Resolution